Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7897374 | 1.00 | MAPT (0.35) | MAPTCYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL27873729 | 1.00 | MAPT (0.35) | MAPTCYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL17190969 | 0.78 | PARP1 (0.41) | MAPTCYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL27873727 | 0.77 | PARP10 (0.40) | MAPTKDM4E | |
| SCHEMBL1857350 | 0.77 | PARP10 (0.40) | MAPTKDM4E | |
| SCHEMBL159742 | 0.77 | SRD5A1 (0.39) | MAPTKDM4EHTR1A | |
| SCHEMBL27873730 | 0.77 | SRD5A1 (0.39) | MAPTKDM4EHTR1A | |
| SCHEMBL7897372 | 0.77 | SRD5A1 (0.39) | MAPTKDM4EHTR1A | |
| SCHEMBL7897504 | 0.77 | KDM4E (0.31) | MAPTKDM4E | |
| SCHEMBL168071 | 0.77 | PARP10 (0.40) | MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8367836-B2 | Pyridinone antagonists of alpha-4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2424841-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | Elan Pharmaceuticals Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110009407-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| WO-2010126914-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252957-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ITGA4, ITGB4, ITGB5 | MAPT 248/4885CYP1A2 2293/4885CYP3A4 556/4885 |
| US-20110009407-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ITGA4, ITGB4, ITGB5 | MAPT 248/4885CYP1A2 2293/4885CYP3A4 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.